 This is a very interesting study because it is a study that may be a one time study that shows us a real randomized trial which is actually checking one drug versus the other. Interestingly enough, there is another abstract from the IHA showing that the most common treatment today in A. L. Amidoidosi's first line is Cyborg D. Meaning that most patients will get cyclophosphamide or Tezumibindexumetazone as the first line and it is a very effective medication or combination of treatments. So a real question would be whether if we add dartumab which is an antibody against CD38, it's very effective in myeloma and certainly we've seen in large series that it is also very effective in relapsed amyloidosis but in first time of myeloidosis it has never been tested. And for the past year there have been a few trials of dartumab added to standard therapy in myeloma showing very good efficacy but here comes amyloidosis and here in this trial the patients were randomized, there were quite a lot of patients, there were 388 patients that were randomized into two groups. One group of almost 200 patients receiving dartumab with the cyborg D with the cyclophosphamide or Tezumibindexumetazone and the other group was receiving just the cyborg D. This was going for six cycles as standard treatment and then the group of the patients treated with dartumab would continue as a maintenance therapy for a while meaning two years and the other group treatment was stopped and was observed for long-term response and whatever the end points were but the main end point, the primary end point of this trial is to see the overall hematologic complete remission rate and why is that? It's because we know that in amyloidosis the response rate is one of the most important things when we want to assess the ability of the patients not only to survive but also to maintain his organ function. Amyloidosis is characterized by organ dysfunction much more than myeloma, this organ dysfunction is what will, a long time, be the main prognostic factor of the patient, both survival and effect, it's life because most patients would have cardiac involvement. So in this trial there were quite many patients that were with cardiac involvement actually about third of the patients had severe cardiac involvement meaning that this is not an easy population of patients that are being treated and also most patients kind of 60 or 70 percent of the patients had some kind of cardiac involvement and also 60 percent of the patients had kidney involvement as well. So these are typical amyloid patients and they are patients whom we see in our everyday clinic and they were treated in this regimen and the results were very, very good in terms of the patient outcome and I'll explain in a moment. Interestingly the patients who were on the cyborg detreatment, although most of them had nice responses, about 42 percent of them after finishing the cyborg detreatment already have been receiving a subsequent therapy which is actually dartoma but a subsequent therapy. But still we see very, very good results with just first-line dartoma and what do I mean? First of all as I said the primary endpoint is hematologic complete remission which is a predictor of both survival, long-term survival and a predictor of organ response. And what we can see is that about half of the patient had a complete hematologic remission which is much more than the cyborg detreatment patients which only about a fifth of the patient have achieved this very deep response. So this is already very, very, very encouraging and actually this has been seen in all patients even if they had renal disease, even if they had cardiac or even severe cardiac disease. Actually those patients with the severe cardiac disease are the ones with the best responses for some reason. And also patients with changes in their genetic changes in their cells which makes them sometimes a little bit resistant to bortezum. We know that patients with translocation 11-14 have some sort of resistance. And so these response is a very good response even in 11-14 translocated cells of these patients. So the overall response rate was also very good but this we know is very good also in the cyborg D in the regular treatment where almost 80% will have some sort of response. But only 50% of the patients here had a very good partial response or complete remission. Whereas in the dartumum of arm 80% of the patients had a very good partial remission or better as I said 50% had complete remission. And this has translated into organ deterioration which is what we want to see. We want to see that these patients will ameliorate their organ dysfunction. So most of the patients with the dartumum had major organ dysfunction ameliorated. Whereas only half of the patients with the cyborg D managed to do that. And so this is very impressive and this is very important in terms of amelioratosis. And so the organ response in a way that the heart is getting better that we can measure it by biomarkers or renal response meaning that the protein in the urine is less than it was. So we can see that these responses were about doubled with the dartumum. So this is very impressive and the most important thing is that this did not come. There were a little bit more infections. But this did not come with severe side effects added to the cyborg D basic protocol. So this is very encouraging both because dartumum now in this trial was giving subcutaneously meaning that it was very convenient for the patients. We were fearing that maybe cardiac patients would have severe shortness of breath or other or other transfusion related events. And no, it did not happen. And actually dartumum was very, very safe. So in conclusion, I would say that dartumum was shown to be superior to cyborg D, the Velcae Bortesomy based therapy alone. It resulted in deeper and more rapid hematologic responses. And this treatment did delay organ dysfunction or duration and it improved the organ survival. There was no, we do know that amyloidosis quite like myeloma may cause also death of the patient so that some of the patient died. Of course, we do know that it happens at the same rate, but it is really too early to say in the long run if this is going to change. But the major thing that we wanted to see from this trial is that the dartumum does affect the organ dysfunction. This has been showing very beautifully. Well, actually this trial was based, unlike in myeloma where dartumum was given in fourth line, then in second line, then now in first line in clinical trials in amyloidosis. There were no clinical trials done in second, third, fourth line, but there is a very much growing experience, an article that was published from many centers showing a very profound effect of dartumum in treatment of amyloidosis. This has been our experience as well. One of these abstracts was coming from Israel and there we had almost 50 patients treated in some of them in fourth, fifth, sixth line treatment with dartumum and achieving very nice results. And what is more encouraging is the fact that with dartumum we can get very prolonged responses sometimes. So many patients will receive it even in fourth or fifth line and still will maintain remission for a very, very long time. And this is very encouraging. And I think the reason for it is probably because the advantage of amyloidosis is that it's not a very proliferative disease, meaning that the load of disease is low and dartumum, even as a single agent, can sometimes overcome this low load of proliferative disease and maintain this complete remission rate in a way this organ response rate for a very long time. Well, as usual in amyloidosis, these abstracts are sometimes quoting small series of patients, as I said, with dartumum, of course, which is a very impressive results even in later lines. And there are starting to be reports of newer medications. Basically, we're talking about venetoclax for 11 translocation, 11-14 patients. We do know that 11-14 patients are sometimes resistant to bortezumine, especially in amyloidosis. And although in myeloma they are not high risk patients, they will relapse like any other patients. And so for some technical or mechanical reason, venetoclax is a small molecule that interferes in the cell survival. And it works mostly in these patients that their cells harbor this translocation, the 11-14 translocation. And therefore, venetoclax seems as in amyloidosis about 50% of patients, or almost 50% of patients will have this translocation. This seems like a kind of a very promising drug for these patients. And actually, there are a few abstracts in the IHA. One of them is the one showing the largest series to date. It's not a lot of patients. I think it's seven or eight patients. But all of them responded very well. This comes as well as my own experience showing that venetoclax gives a profound response in amyloidosis patients, even when it's given in fourth, fifth, or sixth time. Steel patients have a very, very deep responses and prolonged responses. So this is very encouraging as well. Well, I think the next big trial would be a trial that is supposed to be or starting to open right now, which is a trial once again utilizing an antibody that dissolves or supposedly dissolves the amyloid. It's called K-1-1. It's an antibody like previous antibodies that were very promising in a way, but did not work. This one seems to be with very high affinity to the amyloid. And it's very promising in terms of the phase one and two, the first phases of trials that we're testing, showing that it did amyloid organs and organ responses in a amyloidosis patient. So now it's going to be given in first line with the standard treatment, as we said, Portesimib-Cybert D protocol. And when added, we hope that eventually we will see this, that it will help these patients at first line. And probably if it will, then we can continue and test it in other lines. Otherwise, we hope that soon enough there will be a large trial all over the world using this Veneto-Clax that I spoke about in relapsing patients with amyloidosis because at least half of them have this translocation 1114.